Cosmos Health Inc. Reports Q2 2025 Revenue Growth of 11.7% to $14.7 Million

Cosmos Health Inc. reported its financial results for the second quarter of 2025, revealing a revenue of $14.7 million, a notable increase of 11.7% from $13.2 million in the same period last year. For the first half of 2025, the company generated $28.5 million in revenue, up 2.4% from $27.8 million in the prior year. Despite the revenue growth, the company recorded a net loss of $2.8 million for the quarter, compared to a loss of $2.6 million in Q2 2024. The six-month net loss was $3.6 million, an improvement from a loss of $4.5 million in the same period last year.

The increase in revenue was primarily driven by higher sales from its subsidiaries, particularly SkyPharm and Cana. SkyPharm's sales of the proprietary nutraceutical line, Sky Premium Life, saw significant growth in markets such as the UAE and Cyprus. Cana, which was acquired in June 2023, contributed to revenue through new contract manufacturing agreements. The gross profit for the quarter was $1.2 million, reflecting a 51.7% increase compared to the previous year, attributed to a favorable shift towards higher-margin products.

Operationally, Cosmos Health has made strategic moves, including the acquisition of Cloudscreen, an AI-powered platform for drug repurposing, and the expansion of its distribution network in the UAE. The company also reported an increase in its employee headcount, which contributed to a rise in operating expenses, particularly in salaries and wages, which increased by 28.4% in Q2 2025 compared to the previous year. The total operating expenses for the quarter were $3.8 million, up 16.5% from $3.3 million in Q2 2024.

As of June 30, 2025, Cosmos Health had total assets of $61.8 million, up from $54.3 million at the end of 2024. However, the company reported negative working capital of $604,249, indicating challenges in meeting short-term obligations. The company’s cash and cash equivalents increased to $655,503 from $315,105 at the end of 2024, but it continues to rely on external financing to support operations and growth initiatives. Management plans to expand its product portfolio and distribution channels, particularly in the UAE, and is exploring additional financing options, including a recent agreement to issue up to $300 million in convertible promissory notes.

Looking ahead, Cosmos Health remains focused on enhancing its operational efficiencies and expanding its market presence. The company aims to leverage its recent acquisitions and partnerships to drive revenue growth while addressing its liquidity challenges. Despite the ongoing losses, management expresses optimism about future cash inflows from secured agreements and new product launches, which are expected to contribute positively to the company's financial performance in the coming months.